tetano
Editor, Senior Moderator
Immunol Invest
. 2021 Apr 8;1-11.
doi: 10.1080/08820139.2021.1909617. Online ahead of print.
Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
Jenna M Bartley[SUP] 1 [/SUP], Andreia N Cadar[SUP] 1 [/SUP], Dominique E Martin[SUP] 1 [/SUP]
Affiliations
Abstract
Older adults have diminished immune responses that lead to increased susceptibility and severity of infectious diseases. Influenza is a leading killer of older adults despite the availability of seasonal influenza vaccination. Influenza vaccines are strain specific, and their efficacy varies greatly year to year based on how well the vaccine virus matches the circulating strains. Additionally, older adults have reduced vaccination responses. The COVID-19 pandemic highlighted the increased mortality rate in older adults for infectious disease, and brought vaccine development to the forefront. The speed of vaccine development was met with an equally impressive vaccine efficacy. Interestingly, both mRNA-based COVID-19 vaccines currently available have shown similar efficacy in both young and older adults. mRNA vaccine production has significantly reduced the production timeline compared to current influenza vaccines, making them particularly attractive for influenza vaccine development. Faster production coupled with improved efficacy would be a tremendous advancement in protecting older adults from influenza morbidity and mortality.
Keywords: Influenza vaccination; aging; mRNA vaccines; older adults; vaccine efficacy.
. 2021 Apr 8;1-11.
doi: 10.1080/08820139.2021.1909617. Online ahead of print.
Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
Jenna M Bartley[SUP] 1 [/SUP], Andreia N Cadar[SUP] 1 [/SUP], Dominique E Martin[SUP] 1 [/SUP]
Affiliations
- PMID: 33830864
- DOI: 10.1080/08820139.2021.1909617
Abstract
Older adults have diminished immune responses that lead to increased susceptibility and severity of infectious diseases. Influenza is a leading killer of older adults despite the availability of seasonal influenza vaccination. Influenza vaccines are strain specific, and their efficacy varies greatly year to year based on how well the vaccine virus matches the circulating strains. Additionally, older adults have reduced vaccination responses. The COVID-19 pandemic highlighted the increased mortality rate in older adults for infectious disease, and brought vaccine development to the forefront. The speed of vaccine development was met with an equally impressive vaccine efficacy. Interestingly, both mRNA-based COVID-19 vaccines currently available have shown similar efficacy in both young and older adults. mRNA vaccine production has significantly reduced the production timeline compared to current influenza vaccines, making them particularly attractive for influenza vaccine development. Faster production coupled with improved efficacy would be a tremendous advancement in protecting older adults from influenza morbidity and mortality.
Keywords: Influenza vaccination; aging; mRNA vaccines; older adults; vaccine efficacy.